Figure 12
From: Nectin-2 is a potential target for antibody therapy of breast and ovarian cancers
In vivo anti-tumor effect of Y-443 IgG 1 versus Y-443 IgG 4 in the established MDA-MB-231 mouse subcutaneous xenograft model. MDA-MB-231 cells were injected into SCID mice, and the mice were then treated with Y-443 IgG1 (A) or Y-443 IgG4 (B) on days 36, 43, and 50 after cell injection (n = 5). The results are the mean ± S.D. *: p < 0.025 versus the control as determined by the one-tailed Williams test.